addiction | GenomeWeb

addiction

The agency is seeking grant applications for projects investigating the molecular genetics underlying drug addiction and related co-morbidities.

A company says its tests may be able to help avert opioid addiction, CNBC reports.

Jax researchers will aim to study why some individuals are more likely to start using drugs, or to get addicted to them.

The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction. 

A genome-wide association study of participants from three substance dependence cohorts led to variants in some of the same genes linked to psychiatric disease.

NEW YORK (GenomeWeb News) – The National Institute on Drug Abuse plans to fund research and development projects investigating the genomic characteristics and molecular pathways that may play roles in addiction.

NEW YORK (GenomeWeb News) –The National Institute on Drug Abuse plans to fund research efforts to develop new methods for sequencing, mapping, and analyzing genomes of animals that have been bred to have traits related to addiction, with the aim of identifying gene variants that may be involved i

Drug testing lab Dominion Diagnostics and nutrigenomics firm LifeGen announced an agreement last month giving Dominion exclusive licensing rights to a biomarker signature LifeGen has developed to predict a patient's risk for addiction.

NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.

NEW YORK (GenomeWeb News) – Researchers at George Washington University School of Medicine and Health Sciences and the University of Maryland School of Medicine will use a $405,000 grant from the National Institute on Drug Abuse to investigate genes that may increase susceptibility to drug abuse

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.